Acorda Therapeutics to Present New Research on AMPYRA® (dalfampridine-ER) at 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new research at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC